Alembic Pharmaceuticals gets final nod for Fulvestrant Injection from USFDA

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per SingleDose Prefilled Syringe.

alembic pharmaceuticals gets usfda approval for solifenacin succinate tablets
Alembic Pharmaceuticals

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP. Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of breast cancer.

Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of $71 million for twelve months ending September 2022 according to IQVIA. Alembic has received a cumulative total of 179 ANDA approvals (156 final approvals and 23 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Check Also

A Colorful Affair: Rainbow Children’s Hospital’s Grand Baby Shower for Expectant Parents

Rainbow Children’s Hospital, hosted a “Grand Baby Shower” event, at the exquisite Fortune Select Trinity …

Leave a Reply

Your email address will not be published. Required fields are marked *